SOPHiA GENETICS SA (NASDAQ: SOPH)

SOPHiA GENETICS SA is a cloud-native software technology company dedicated to advancing data-driven medicine in healthcare. The company's core product the SOPHiA DDM platform standardizes computes and analyzes digital health data from diverse sources including genomic radiomic and clinical datasets to generate clinically actionable insights. This enables healthcare institutions to break down data silos and build collective intelligence through a decentralized network where customers perform testing on their own samples retain custody of data and share pseudonymized insights globally. The platform supports applications across oncology rare diseases infectious diseases cardiology neurology metabolism and other therapeutic areas to improve diagnosis treatment and drug development.

SOPHiA GENETICS SA generates revenue primarily through access to its SOPHiA DDM platform under three main models: dry lab access where customers use their own sequencing equipment with the platform's analytics bundle access which combines third-party instruments with the platform's solution and integrated access where the company facilitates sequencing through its partner network. The primary pricing strategy for clinical customers is a pay-per-use model with fees applied per analysis performed. Additional revenue streams include the Alamut suite for genomic interpretation and specialized biopharma applications such as SOPHiA Insights for real-world evidence SOPHiA Trial Match for patient recruitment SOPHiA CDx for companion diagnostics and SOPHiA Awareness for market intelligence. Commercialization leverages a direct sales force of over 105 representatives and distributor partners covering 75 countries.

SOPHiA GENETICS SA occupies a leading position as one of the most widely used decentralized analytics platforms for clinical genomics worldwide. The company distinguishes itself through its cloud-native architecture that enables seamless integration with diverse laboratory workflows while ensuring customer data remains under local control. Key competitors encompass integrated diagnostics enterprises such as Roche and specialized players like Tempus Labs alongside genomic software companies including Illumina Agilent and Qiagen. Competitive advantages derive from the scale of its global network which continuously refines its AI algorithms through accumulated real-world data and from its unique capability to support multi-omic analysis combining genomics with radiomics and clinical data to generate deeper disease insights.

As of December 31 2025 SOPHiA GENETICS SA served more than 993 hospital laboratory and biopharmaceutical customers across the globe. The customer base comprises academic and non-academic hospitals including comprehensive cancer centers and children's hospitals reference laboratories specialty laboratories and pharmaceutical biotechnology companies. Through its platform the company has enabled analysis of approximately 2300000 genomic profiles with recent growth of about 33000 new monthly additions. This activity has contributed to over 2712 peer-reviewed publications and supports users in 75 countries via a direct sales team present in 60 nations and distributor partnerships in an additional 50 regions.